中枢性厌食动物模型的建立及健脾消食中药的干预作用
|
摘要
研究背景和目的
健脾消食类中药是中药中较有特色的一类。该类中药对由食积停滞所致的脘腹胀满、嗳气泛酸、恶心呕吐、不思饮食、泄泻或便秘等症有较好的治疗效果。目前该类中药的药理学研究多是从其对胃肠运动和胃肠功能的影响方面着手,国内尚少见涉及调节中枢神经系统中药药理研究的文献报道。
厌食症是较常见的食欲不振的疾病,本实验拟将厌食症作为研究对象。目前研究厌食的动物模型大都直接采用脾虚动物模型,临床上厌食症的中医证型不一,例如有脾失健运、脾胃虚弱、胃阴不足、虚实夹杂等证型,脾虚只是其中证型之一。因机体调节食欲的中枢在神经系统,厌食的根本原因在于中枢神经系统调控失常,故本研究拟建立符合致病原因的中枢抑制性厌食症动物模型,为厌食症的药理学研究提供参考依据。
瘦素(Leptin,LP)是肥胖基因的产物,是白色脂肪细胞分泌的一种由167个氨基酸残基组成的蛋白质。Leptin可与下丘脑进食中枢的leptin受体相结合,抑制NPY及AgRP神经元的表达,抑制食欲,也可与饱食中枢的leptin受体结合,促使前鸦片黑皮质素原(POMC)神经元分泌前鸦片黑皮质素原,代谢为鸦片黑皮质素,作用于鸦片黑皮质素-4和鸦片黑皮质素-3受体,引起食欲降低及机体能量消耗增加。
CCK参与胃肠功能的调节,并作为饱感信号起抑制食欲的作用,是外周摄食调节的主要生理因子;本文实验二研究发现多个剂量的CCK单独腹腔注射都没有抑制食欲和降低体重的作用。文献报道CCK短期抑制食欲的激素,可与长期影响脂肪沉积继而影响能量代谢的LP协同作用,共同参与中枢的摄食调节。CLAIRE报道LP50μg/kg单独腹腔注射可以降低大鼠进食量,LP 50μg/kg和8～16μg/kgCCK联合腹腔注射效果更佳,两者联合腹腔注射后与LP单独腹腔注射后大鼠食量比较差异有统计学意义,Scott等报道第三脑室注射LP 7μg/kg和腹腔注射CCK 2μg/kg都有降低食欲的作用。Kiely则发现给LP缺乏的肥胖大鼠腹腔注射LP 5μg/kg一个月,可增加大鼠十二指肠和结肠CCK表达,推测认为LP抑制食欲的作用可能通过作用于外周胃肠CCK起效。
NPY是下丘脑最重要的食欲促进因子。CCK可能是通过作用于LP发挥抑制食欲的作用,而LP和CCK的抑制食欲的作用都要通过下丘脑NPY起效。脑室和腹腔注射瘦素能明显抑制下丘脑NPY的合成和释放。
山楂麦芽颗粒是中山中智药业集团的产品,主要由消食和健脾两类中药组成,临床取得较好的疗效,本实验室药效学研究也表明该产品有较好的促进动物胃肠运动和提高动物进食量并促体重增长的作用。香砂六君子汤是著名古方,对脾虚气滞或痰瘀引起的食欲不振有较好效果。本课题拟建立中枢抑制性厌食症动物模型,用于观察山楂麦芽颗粒和香砂六君子汤的药理作用,从脑肠肽-食欲调节中枢角度探讨健脾消食类中药作用机制。
研究方法
1.筛选几种厌食症动物模型的造模方法,包括给幼龄大鼠喂养由鸡蛋、奶粉、五花肉、白糖等制成的高营养饲料模型,腹腔注射缩胆囊素模型,腹腔单用及联合注射缩胆囊素和瘦素模型,侧脑室预置套管注射瘦素模型等。
2.在成功建立的中枢抑制性厌食症大鼠模型上,主要观察造模对大鼠整体状态、体重和进食量的影响,检测对进食起关键作用的下丘脑神经肽Y和血浆神经肽Y(NPY,一种脑肠肽)含量,探讨造模后对大鼠脑肠肽-食欲中枢的影响。观察山楂麦芽颗粒和香砂六君子汤水提液对模型大鼠的治疗作用,并检测下丘脑和血浆神经肽Y含量。
3.建立山楂麦芽颗粒质量控制的定性定量检测指标;药效学实验观察山楂麦芽颗粒对动物胃肠运动和进食量等的影响。
结果
1.给幼龄大鼠喂养高营养饲料的造模方法可导致动物进食量降低,也能使动物体重增加非常缓慢,但停止造模并恢复给正常饲料后,大鼠体重和进食量都快速增加,造模期间大鼠厌食的原因在于这种由各类高脂肪高蛋白物质构成的食物不符合大鼠的进食习惯,并非食欲降低;缩胆囊素3个剂量5μg/kg、10μg/kg和20μg/kg腹腔注射均没有降低大鼠食欲的作用;缩胆囊素和瘦素单用及联合腹腔注射也没有降低动物食欲的作用;可能是由于动物吸收不好或药物作用时间过短等原因,致使造模药物不能抑制食欲。
2.采用侧脑室注射瘦素的方法成功建立了厌食症动物模型。其方法为先给大鼠侧脑室置管(以300g左右大鼠为例,套管针埋在前囟后1.5cm,旁开1.5cm,深度4.0mm比较合适),大鼠置管并正常饲养1周后,给大鼠脑室注射瘦素每日1次共7天,剂量10μg/kg/20μL,注射速度约1μL/min。造模后大鼠平均每天进食13g左右饲料,体重平稳下降,平均每天6～10g左右。造模结束处死大鼠,放射免疫法检测NPY,结果造模大鼠下丘脑NPY含量显著降低(正常组下丘脑NPY平均含量为22.2ng/ml,模型组下丘脑NPY平均含量为14.8ng/ml,P＜0.05)。
3.山楂麦芽颗粒8g/kg(药效学实验有效剂量,临床用量的9倍)和香砂六君子汤13.6g/kg(临床用量的15倍)对侧脑室注射瘦素致厌食症大鼠有一定治疗作用,虽没有提高动物进食量,但在一定程度提高动物体重,其中香砂六君子汤能提高大鼠下丘脑NPY含量(模型组下丘脑NPY平均含量为14.8ng/mL,香砂六君子汤组NPY平均含量为20.3ng/mL,P＜0.05)。
4.建立了山楂麦芽颗粒的定性定量质量标准:高效液相法检测山楂麦芽颗粒中陈皮主要成份橙皮苷的含量,薄层色谱法定性鉴别山楂、麦芽和陈皮。药效学实验表明山楂麦芽颗粒8g/kg对动物胃肠运动及提高进食量和体重有效。
结论
侧脑室注射瘦素致中枢性厌食症大鼠模型,造成大鼠适度的厌食和体重降低,并能抑制下丘脑NPY表达,与机体食欲调节的机制原理相符,其致厌食的原理与厌食症发病机理类似,健脾消食中药山楂麦芽颗粒和香砂六君子汤对该模型大鼠有一定治疗作用,其中香砂六君子汤作用机制可能与下丘脑NPY调节有关,所以该模型可用于厌食症的治疗机理研究,也适合用于其它健脾消食中药的药理研究。
Backgrounds and aims
Invigorating spleen Chinese medicines to promote digestion are of much more features in the whole of Chinese medicines,those Chinese medicines can obtain some good effects in treating such diseases as abdominal,belch,bepanthen,nausea and vomiting, anorexia,diarrhoea,adstricto,etc,resulting from fresh plot stagnation.At present, pharmacological researchs for those kinds of Chinese medicine almost began with studying the drug effect in stomach intestine & function,there is few literatures about pharmacological research for Chinese medicine in respect of adjusting central nervous system at home.
We intend to take apositia as the object of study,which is a disease of losing appetite frequently occurred.At present,most of studies of apositia began at first to adopt animal model of splenic asthenia,there are many patterns of syndrome of apositia in the clinical practices,the model of splenic asthenia cannot represent all the models of apositia.The center of adjusting the appetite in the body activities lies in the nervous system,the root cause of apositia is controlling disorder of the central nervous system,this sdudy intends to establish an animal model of apositia with the function of central inhibition according to the cause of disease to give some reference for pharmacological research of apositia.
Shanzha Maiya granula is the product of Zhongshan Zhongzhi Medical Industrial Group Coporation Ltd,mainly composed of two kinds of medicines promoting digestion and invigorating the spleen,with good effect in the clinical trial,this Laboratory's pharmacodynamic research also illustrates that this product can play an important role in promoting stomach intestine and increasing the animal's weight & food intake.Decoction of Xiangshasix Mild Drugs is a classical prescription of long history,which has good effect in treating the loss of appetite arising from Qi stagnant or sputum stasis.This topic intends to set up the animal model of apositia with the function of central inhibition to investigate the pharmacological effect of Shanzha Maiya granula and research the functional mechanism of the Chinese medicines for invigorating spleen to promote digestion in view of braingut petide-appestat.
Methods of research
1.screening some methods of setting up the animal model for children's loss of appetite,including feeding the young mouse with the feeder of high nutrition made of eggs, milk,pork,sugar,etc;intraperitoneal injection of Cholecystokinin(CCK);intraperitoneal combined injection of Cholecystokinin(CCK) and Leptin(LP);pre-setting canula to inject LP in the lateral cerebral ventricle,etc.
2.on the basis of successfully establishing the animal model of apositia,concentrates on investigating the model's effect on the mouse's whole pattern,weight and food intake, detecting the content of neuropeptide Y in the mouse's hypothalamus & blood plasm,which plays key role in eating,and mastering the medicine's effect on the mouse's braingut petide-appestat after setting up the animal model.Investigate the medical effect of the water extract of Decoction of Xiangsha six Mild Drugs and Shanzha Maiya granula on the model mouse,and detect the content of NPY in hypothalamus & blood plasm.
3.set up the indicators of qualitatively and quantitatively detecting Shanzha Maiya granula,and investigate the pharmacodynamics indicator of the Shanzha Maiya granula's effect on the animal's stomach intestine & food-intake,etc.
Results
1.the model method of feeding the young mouse with the feeder of hyperalimentation may make the mouse to eat less,and make the mouse' weight to increase slowly, however,after stopping the model method and returning to feed the mouse normally,the mouse' weight & food-intake increase quickly.During the time of making the model,the cause of the mouse's apositia is the mouse disliking those foods composed of high-fat & high-protein substances,not loss of appetite;none of the 3 groups of intraperitoneal injection of 5μg/kg,10μg/kg,20μg/kg Cholecystokinin(CCK) can make the mouse's appetite to lower;the intraperitoneal combined injection of Cholecystokinin(CCK) and Leptin(LP) cannot make the animal's appetite to lower,it is likely that the medicine's failure to inhibit the appetite results from the animal's bad absorption or the time of the medicine taking effect being too short,etc.
2.establishing successfully the animal mode of apositia through injecting Leptin (LP).This method can be illustrated as follows:at first,set canula in the lateral cerebral ventricle of mouse(take the mouse weighting about 300 grams as example,it is fit to bury the canula needle in 1.5cm after anterior fontanel,1.5cm left or right,4ram deep);after the mouse's recovery for a week,inject in the every day the mouse with the dose of 10μg/20μl/kg leptin at speed of about 1 macro-litre as per minute.After making the model, the mouse eats about 13 gram of feeder everyday,its weight reduces steadily about 6-10 gram everyday on the average.After the termination of the model,kill the mouse,detect NPY and then see the content of NPY in the Hypothalamus of the mouse significantly lower.
3.8g/kg(it is valid dose proved by pharmacodynamic experiment,about 9 times of human dose) of Shanzha Maiya granula and 13.6g/kg(15 times of human dose) of Decoction of Xiangsha six Mild Drugs can play a certain role in treating the animal model of child apositia resulting from leptin,fail to increase the animal's food-intake,but can increase its weight to some extent,Decoction of Xiangsha six Mild Drugs can increase the content of NPY in the Hypothalamus of the mouse.
4.set up quality standard of qualitatively and quantitatively detecting Shanzha Maiya granula:detecting the content of aurantiamarin as a main component of Chenpi in Shanzha Maiya granula through the method of high performance liquid phase,qualitatively identifying Shanzha,Maiya,Chenpi through the method of plate chromatography.The pharmacodynamic experiments illustrate that 8g/kg of Shanzha Maiya granula's effect is the best in promoting stomach intestine,increasing food-intake and weight.
Conclusion
The mouse model of intraperitoneal injection of leptin causing apositia which makes the mouse's appetite & weight to lower,can inhibit expression of NPY in hypothalamus, conform to the principle about mechanism of body appetite's adjustment,so the principle of the model causing apositia is similar with the incidence mechanism of apositia,Shanzha Maiya granula and Decoction of Xiangsha six Mild Drugs as Chinese medicines for invigorating spleen to promote digestion can play an important role in treating the model mouse,the functional mechanism of Decoction of Xiangsha six Mild Drugs is related to adjustment of NPY in hypothalamus,so this model which is used to researching the mechanism of treating child apositia,also may be used as pharmacological model fit for other Chinese medicines for invigorating spleen to promote Qi.
健脾消食类中药是中药中较有特色的一类。该类中药对由食积停滞所致的脘腹胀满、嗳气泛酸、恶心呕吐、不思饮食、泄泻或便秘等症有较好的治疗效果。目前该类中药的药理学研究多是从其对胃肠运动和胃肠功能的影响方面着手,国内尚少见涉及调节中枢神经系统中药药理研究的文献报道。
厌食症是较常见的食欲不振的疾病,本实验拟将厌食症作为研究对象。目前研究厌食的动物模型大都直接采用脾虚动物模型,临床上厌食症的中医证型不一,例如有脾失健运、脾胃虚弱、胃阴不足、虚实夹杂等证型,脾虚只是其中证型之一。因机体调节食欲的中枢在神经系统,厌食的根本原因在于中枢神经系统调控失常,故本研究拟建立符合致病原因的中枢抑制性厌食症动物模型,为厌食症的药理学研究提供参考依据。
瘦素(Leptin,LP)是肥胖基因的产物,是白色脂肪细胞分泌的一种由167个氨基酸残基组成的蛋白质。Leptin可与下丘脑进食中枢的leptin受体相结合,抑制NPY及AgRP神经元的表达,抑制食欲,也可与饱食中枢的leptin受体结合,促使前鸦片黑皮质素原(POMC)神经元分泌前鸦片黑皮质素原,代谢为鸦片黑皮质素,作用于鸦片黑皮质素-4和鸦片黑皮质素-3受体,引起食欲降低及机体能量消耗增加。
CCK参与胃肠功能的调节,并作为饱感信号起抑制食欲的作用,是外周摄食调节的主要生理因子;本文实验二研究发现多个剂量的CCK单独腹腔注射都没有抑制食欲和降低体重的作用。文献报道CCK短期抑制食欲的激素,可与长期影响脂肪沉积继而影响能量代谢的LP协同作用,共同参与中枢的摄食调节。CLAIRE报道LP50μg/kg单独腹腔注射可以降低大鼠进食量,LP 50μg/kg和8～16μg/kgCCK联合腹腔注射效果更佳,两者联合腹腔注射后与LP单独腹腔注射后大鼠食量比较差异有统计学意义,Scott等报道第三脑室注射LP 7μg/kg和腹腔注射CCK 2μg/kg都有降低食欲的作用。Kiely则发现给LP缺乏的肥胖大鼠腹腔注射LP 5μg/kg一个月,可增加大鼠十二指肠和结肠CCK表达,推测认为LP抑制食欲的作用可能通过作用于外周胃肠CCK起效。
NPY是下丘脑最重要的食欲促进因子。CCK可能是通过作用于LP发挥抑制食欲的作用,而LP和CCK的抑制食欲的作用都要通过下丘脑NPY起效。脑室和腹腔注射瘦素能明显抑制下丘脑NPY的合成和释放。
山楂麦芽颗粒是中山中智药业集团的产品,主要由消食和健脾两类中药组成,临床取得较好的疗效,本实验室药效学研究也表明该产品有较好的促进动物胃肠运动和提高动物进食量并促体重增长的作用。香砂六君子汤是著名古方,对脾虚气滞或痰瘀引起的食欲不振有较好效果。本课题拟建立中枢抑制性厌食症动物模型,用于观察山楂麦芽颗粒和香砂六君子汤的药理作用,从脑肠肽-食欲调节中枢角度探讨健脾消食类中药作用机制。
研究方法
1.筛选几种厌食症动物模型的造模方法,包括给幼龄大鼠喂养由鸡蛋、奶粉、五花肉、白糖等制成的高营养饲料模型,腹腔注射缩胆囊素模型,腹腔单用及联合注射缩胆囊素和瘦素模型,侧脑室预置套管注射瘦素模型等。
2.在成功建立的中枢抑制性厌食症大鼠模型上,主要观察造模对大鼠整体状态、体重和进食量的影响,检测对进食起关键作用的下丘脑神经肽Y和血浆神经肽Y(NPY,一种脑肠肽)含量,探讨造模后对大鼠脑肠肽-食欲中枢的影响。观察山楂麦芽颗粒和香砂六君子汤水提液对模型大鼠的治疗作用,并检测下丘脑和血浆神经肽Y含量。
3.建立山楂麦芽颗粒质量控制的定性定量检测指标;药效学实验观察山楂麦芽颗粒对动物胃肠运动和进食量等的影响。
结果
1.给幼龄大鼠喂养高营养饲料的造模方法可导致动物进食量降低,也能使动物体重增加非常缓慢,但停止造模并恢复给正常饲料后,大鼠体重和进食量都快速增加,造模期间大鼠厌食的原因在于这种由各类高脂肪高蛋白物质构成的食物不符合大鼠的进食习惯,并非食欲降低;缩胆囊素3个剂量5μg/kg、10μg/kg和20μg/kg腹腔注射均没有降低大鼠食欲的作用;缩胆囊素和瘦素单用及联合腹腔注射也没有降低动物食欲的作用;可能是由于动物吸收不好或药物作用时间过短等原因,致使造模药物不能抑制食欲。
2.采用侧脑室注射瘦素的方法成功建立了厌食症动物模型。其方法为先给大鼠侧脑室置管(以300g左右大鼠为例,套管针埋在前囟后1.5cm,旁开1.5cm,深度4.0mm比较合适),大鼠置管并正常饲养1周后,给大鼠脑室注射瘦素每日1次共7天,剂量10μg/kg/20μL,注射速度约1μL/min。造模后大鼠平均每天进食13g左右饲料,体重平稳下降,平均每天6～10g左右。造模结束处死大鼠,放射免疫法检测NPY,结果造模大鼠下丘脑NPY含量显著降低(正常组下丘脑NPY平均含量为22.2ng/ml,模型组下丘脑NPY平均含量为14.8ng/ml,P＜0.05)。
3.山楂麦芽颗粒8g/kg(药效学实验有效剂量,临床用量的9倍)和香砂六君子汤13.6g/kg(临床用量的15倍)对侧脑室注射瘦素致厌食症大鼠有一定治疗作用,虽没有提高动物进食量,但在一定程度提高动物体重,其中香砂六君子汤能提高大鼠下丘脑NPY含量(模型组下丘脑NPY平均含量为14.8ng/mL,香砂六君子汤组NPY平均含量为20.3ng/mL,P＜0.05)。
4.建立了山楂麦芽颗粒的定性定量质量标准:高效液相法检测山楂麦芽颗粒中陈皮主要成份橙皮苷的含量,薄层色谱法定性鉴别山楂、麦芽和陈皮。药效学实验表明山楂麦芽颗粒8g/kg对动物胃肠运动及提高进食量和体重有效。
结论
侧脑室注射瘦素致中枢性厌食症大鼠模型,造成大鼠适度的厌食和体重降低,并能抑制下丘脑NPY表达,与机体食欲调节的机制原理相符,其致厌食的原理与厌食症发病机理类似,健脾消食中药山楂麦芽颗粒和香砂六君子汤对该模型大鼠有一定治疗作用,其中香砂六君子汤作用机制可能与下丘脑NPY调节有关,所以该模型可用于厌食症的治疗机理研究,也适合用于其它健脾消食中药的药理研究。
Backgrounds and aims
Invigorating spleen Chinese medicines to promote digestion are of much more features in the whole of Chinese medicines,those Chinese medicines can obtain some good effects in treating such diseases as abdominal,belch,bepanthen,nausea and vomiting, anorexia,diarrhoea,adstricto,etc,resulting from fresh plot stagnation.At present, pharmacological researchs for those kinds of Chinese medicine almost began with studying the drug effect in stomach intestine & function,there is few literatures about pharmacological research for Chinese medicine in respect of adjusting central nervous system at home.
We intend to take apositia as the object of study,which is a disease of losing appetite frequently occurred.At present,most of studies of apositia began at first to adopt animal model of splenic asthenia,there are many patterns of syndrome of apositia in the clinical practices,the model of splenic asthenia cannot represent all the models of apositia.The center of adjusting the appetite in the body activities lies in the nervous system,the root cause of apositia is controlling disorder of the central nervous system,this sdudy intends to establish an animal model of apositia with the function of central inhibition according to the cause of disease to give some reference for pharmacological research of apositia.
Shanzha Maiya granula is the product of Zhongshan Zhongzhi Medical Industrial Group Coporation Ltd,mainly composed of two kinds of medicines promoting digestion and invigorating the spleen,with good effect in the clinical trial,this Laboratory's pharmacodynamic research also illustrates that this product can play an important role in promoting stomach intestine and increasing the animal's weight & food intake.Decoction of Xiangshasix Mild Drugs is a classical prescription of long history,which has good effect in treating the loss of appetite arising from Qi stagnant or sputum stasis.This topic intends to set up the animal model of apositia with the function of central inhibition to investigate the pharmacological effect of Shanzha Maiya granula and research the functional mechanism of the Chinese medicines for invigorating spleen to promote digestion in view of braingut petide-appestat.
Methods of research
1.screening some methods of setting up the animal model for children's loss of appetite,including feeding the young mouse with the feeder of high nutrition made of eggs, milk,pork,sugar,etc;intraperitoneal injection of Cholecystokinin(CCK);intraperitoneal combined injection of Cholecystokinin(CCK) and Leptin(LP);pre-setting canula to inject LP in the lateral cerebral ventricle,etc.
2.on the basis of successfully establishing the animal model of apositia,concentrates on investigating the model's effect on the mouse's whole pattern,weight and food intake, detecting the content of neuropeptide Y in the mouse's hypothalamus & blood plasm,which plays key role in eating,and mastering the medicine's effect on the mouse's braingut petide-appestat after setting up the animal model.Investigate the medical effect of the water extract of Decoction of Xiangsha six Mild Drugs and Shanzha Maiya granula on the model mouse,and detect the content of NPY in hypothalamus & blood plasm.
3.set up the indicators of qualitatively and quantitatively detecting Shanzha Maiya granula,and investigate the pharmacodynamics indicator of the Shanzha Maiya granula's effect on the animal's stomach intestine & food-intake,etc.
Results
1.the model method of feeding the young mouse with the feeder of hyperalimentation may make the mouse to eat less,and make the mouse' weight to increase slowly, however,after stopping the model method and returning to feed the mouse normally,the mouse' weight & food-intake increase quickly.During the time of making the model,the cause of the mouse's apositia is the mouse disliking those foods composed of high-fat & high-protein substances,not loss of appetite;none of the 3 groups of intraperitoneal injection of 5μg/kg,10μg/kg,20μg/kg Cholecystokinin(CCK) can make the mouse's appetite to lower;the intraperitoneal combined injection of Cholecystokinin(CCK) and Leptin(LP) cannot make the animal's appetite to lower,it is likely that the medicine's failure to inhibit the appetite results from the animal's bad absorption or the time of the medicine taking effect being too short,etc.
2.establishing successfully the animal mode of apositia through injecting Leptin (LP).This method can be illustrated as follows:at first,set canula in the lateral cerebral ventricle of mouse(take the mouse weighting about 300 grams as example,it is fit to bury the canula needle in 1.5cm after anterior fontanel,1.5cm left or right,4ram deep);after the mouse's recovery for a week,inject in the every day the mouse with the dose of 10μg/20μl/kg leptin at speed of about 1 macro-litre as per minute.After making the model, the mouse eats about 13 gram of feeder everyday,its weight reduces steadily about 6-10 gram everyday on the average.After the termination of the model,kill the mouse,detect NPY and then see the content of NPY in the Hypothalamus of the mouse significantly lower.
3.8g/kg(it is valid dose proved by pharmacodynamic experiment,about 9 times of human dose) of Shanzha Maiya granula and 13.6g/kg(15 times of human dose) of Decoction of Xiangsha six Mild Drugs can play a certain role in treating the animal model of child apositia resulting from leptin,fail to increase the animal's food-intake,but can increase its weight to some extent,Decoction of Xiangsha six Mild Drugs can increase the content of NPY in the Hypothalamus of the mouse.
4.set up quality standard of qualitatively and quantitatively detecting Shanzha Maiya granula:detecting the content of aurantiamarin as a main component of Chenpi in Shanzha Maiya granula through the method of high performance liquid phase,qualitatively identifying Shanzha,Maiya,Chenpi through the method of plate chromatography.The pharmacodynamic experiments illustrate that 8g/kg of Shanzha Maiya granula's effect is the best in promoting stomach intestine,increasing food-intake and weight.
Conclusion
The mouse model of intraperitoneal injection of leptin causing apositia which makes the mouse's appetite & weight to lower,can inhibit expression of NPY in hypothalamus, conform to the principle about mechanism of body appetite's adjustment,so the principle of the model causing apositia is similar with the incidence mechanism of apositia,Shanzha Maiya granula and Decoction of Xiangsha six Mild Drugs as Chinese medicines for invigorating spleen to promote digestion can play an important role in treating the model mouse,the functional mechanism of Decoction of Xiangsha six Mild Drugs is related to adjustment of NPY in hypothalamus,so this model which is used to researching the mechanism of treating child apositia,also may be used as pharmacological model fit for other Chinese medicines for invigorating spleen to promote Qi.
引文
[1]欧贤红,林启云,黄小琪.广西大果山楂对小鼠胃肠功能作用的实验研究.广西中医学院学报,2004;7(3):6-9.
[2]王亚红.麦芽在临床中应用说略.河南中医,2003,23(1):60.
[3]胡静,杨旭东,夏清平等.中药“神曲”对脾虚小鼠肠道菌群的调整及肠保护作用研究.中国微生态学杂志,2004;16(4):208-9.
[4]蔡子微,杨旭东,胡静等.中药神曲及其肠道茵群调整和肠保护作用的实验研究.牡丹江医学院学报,2006;27(1):1.
[5]杨继成,华新农,许惠琴等.健胃消食片的药理实验研究.南京中医药大学学报(自然科学版),2001;17(2):104-6.
[6]陈怀礼,庞春霞,李雪岩.健脾消食散对大鼠肠吸收功能的影响,河南中医药学刊,1999;14(6):20.
[7]黄保民,王寿云,李月华.开胃消食口服液对实验动物胃肠功能的影响.中医研究,1998,11(1):21-2.
[8]叶立新,邢英华,张雄等.消食贴膏对小鼠消化道功能的影响.广东药学院学报,2005,21(5):563-4.
[9]葛安霞.健脾片健脾功能的实验研究.中国中西医结合脾胃杂志,2000,8(2):85-87.
[10]Kouhei Matsuda,Kenji Kojima,Sei-Ichi Shimakura,et al.Relationship between melanin-concentrating hormone-and neuropeptide Y-containing neurons in the goldfish hypothalamus.Molecular & Integrative Physiology,2009;153(1):3-7.
[11]Goldstone AP.The hypothalamus,hormones,and hunger:alterations in human obesity and illness.Prog Brain Res,2006;153:57-73.
[12]Williams DL,Baskin DG,Schwartz MW.Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.Endocrinology,2009;150(4):1680-7.
[13]Moran TH.Cholecystokinin and satiety:current perspectives.Nutrition,2000;16(10):858-65.
[14]Verena Haas,Simone Onur,Thomas Paul,et al.Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery.Am J Clin Nutr,2005;81:889-96.
[15]Kojima M,Hosoda H,Date Y,et al.Ghrelin is a rowth-hormone-releasing acylated peptide froms to math.Nature,1999;402(6762):656.
[16]Gema Fruhbeck.Intracellular signalling pathways activated by leptin.Biochem J,2006;393(Pt 1):7-20.
[17]Laurence J,Nolan PhD,Janet L,Guss MS,et al.Elevated plasma cholecystokinin and appetitive ratings after consumption of a liquid meal in humans.Nutrition,2003;6(19):553-7.
[18]Farooqi IS,Matarese G,Lord GM,et al.Beneficial of effects of leptin on obesity,Tcell hypo responsiveness,and neuro endocrine/metabolic dysfunction of human congenital leptind eficiency.JClinlnvest,2002;110(8):1093-103.
[19]Fr(u|¨)hbeck,G.,G(?)mez-Ambrosi,J.,et al.The adipocyte:a model for integration of endocrine and metabolic signaling in energy metabolism regulation.Am J Physiol Endocrinol Metab,2001;280(6):E827-47.
[20]Fr(u|¨)hbeck,G.and G(?)mez-Ambrosi,J.Rationale for the existence of additional adipostatic hormones.FASEB J,2001;15(11):1996-2006.
[21]Mora,S.and Pessin,J.E.An adipocentric view of signaling and intracellular trafficking.Diabetes Diabetes Metab Res Rev,2002;18(5):345-56.
[22]Zhang,Y.,Proenca,R.,Maffei,M.,et al.Positional cloning of the mouse obese gene and its human homologue.Nature,1994;372(6505):425-32.
[23]Banks,W.A.The many lives of leptin.Peptides,2004;25(3):331-8.
[24]Fr'uhbeck,G.A heliocentric view of leptin.Proc.Proc Nutr Soc,2001;60(3):301-18.
[25]Fr'uhbeck,G.Peripheral actions of leptin and its involvement in disease.Nutr Rev,2002;60(10 Pt 2):S47-55.
[18]Baratta,M.Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues.Med Sci Monit,2002;8(12):RA282-92.
[26]Muoio,D.M.and Dohm,G.L.Peripheral metabolic actions of leptin.Best Pract Res Clin Endocrinol Metab,2002;16(4):653-66.
[27]Harvey,J.and Ashford,M.L.J.Leptin in the CNS:much more than a satiety signal.Neuropharmacology,2003;44(7):845-54.
[28]Bj(?)rb(?)ck,C.and Kahn,B.B.Leptin signaling in the central nervous system and the periphery.Recent Prog Horm Res,2004;59:305-31.
[29]Kinik ST,Ozbek N,Yiicel M,et al.Correlations among serum leptin levels,complete blood count parameters and peripheral CD34(+) cell count in prepubertal obese children.Ann Hematol,2005;84(9):605-8.
[30]Gualillo O,Eiras S,White DW,et al.Leptin promotes the tyrosine phosphorylation of SHC proteins and SHC association with GRB2.Mol Cell Endocrinol,2002;190(l-2):83-9.
[31]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[32]Honda K,Kamisoyama H,Saneyasu T,et al.Central administration of insulin suppresses food intake in chicks.Neurosci Lett,2007;423(2):153-7.
[33]Jennifer R McDuffie,Parti A Riggs,Karim A Calis,et al.Effects of Exogenous Leptin on Satiety and Satiation in Patients with Lipodystrophy and Leptin Insufficiency.J Clin Endocrinol Metab,2004;89(9):4258-63.
[34]Wren AM,Seal LJ,Cohen MA,et al.Ghrelin enhances appetite and increases food intake in humans.J Clin Endocrinol Metab,2004;89(6):2832.
[35]de Assis MA,Kupek E,Nahas MV,et al.Food intake and circadian rhythms in shift workers with a high workload.Appetite,2003;40(2):175-83.
[36]Matson CA,Ritter RC.Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight.Am J Physiol,1999;276(4 Pt 2):R1038-45.
[37]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Inter oceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[38]Matson CA,Wiater MF,Kuijper JL,Weigle DS.Synergy between leptin and cholecystokinin(CCK)to control daily caloric intake.Peptides,1997;18(8):1275-8.
[39]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Interoceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[40].McMinn JE,Sindelar DK,Havel PJ,et al.Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.Endocrinology,2000;141(12):4442-8.
[41]Baskin DG,Blevins JE,Schwartz MW.How the brain regulates food intake and body weight:the role of leptin.J Pediatr Endocrinol Metab,2001;14 Suppl 6:1417-29.
[42]Oral EA,Simha V,Ruiz E,et al.Leptin-replacement therapy for lipodystrophy.N Engl J Med,2002;346(25):2009.
[43]S Herguner,Ozyildirim,and G Gokcay.Behavioral approach to infantile anorexia and its outcome on maternal psychopathology.European Psychiatry,2009;24(1):S747.
[44]Chatoor I,Ganiban J,Surles J,Doussard-Roosevelt J.Physiological regulation and infantile anorexia:a pilot study.J Am Acad Child Adolesc Psychiatry.2004;43(8):1019-25.
[45]Poinso F,Viellard M,Dafonseca D,Sarles J.Infantile anorexia:from birth to childhood.Arch Pediatr.2006;13(5):464-72.
[46]Irene Chatoor MD,Jaclyn Surles,BA,Jody Ganiban.Failure to thrive and cognitive development in toddlers with infantile anorexia.Pediatrics,2004;112(5):e440-7.
[47]张丽萍,耿丽,范瑞君.小儿厌食症相关因素调查,武警医学,2008;19(9):784-6.
[48]曾国章.厌食症发病相关因素研究.中国妇幼保健,2008;23(27):3840-1
[49]王研,赵海涛,张劲松等.厌食儿童和正常儿童食物刺激下丘脑功能区fMRI的研究 神经解剖学杂志,2008;24(1):58-62.
[50]陈志凤.厌食症儿童血Ghrelin、Leptin与NPY的水平变化及其临床意义.中国优秀博硕士学位论文全文数据库(硕士),2006,(08).
[51]候菊鲜,岳淑芬,王京红.厌食痖患儿血清中铁锌铜锰硒含量的研究.广东微量元素科学,1999;(2):35-37.
[52]陈美华,罗文莉,张静等.普瑞博斯治疗小儿厌食症疗效观测.白求恩军医学院学报,2004;2(4).
[53]宋春兰,杜开先.口服金双岐治疗小儿厌食症42例.河南预防医学杂志,2007;18(3):224-5.
[54]林顺利,林东浩.双歧杆菌四联活菌片与白苓健脾颗粒联合治疗小儿厌食症.河北医学,2008;14(12).
[55]孟付忠.锌硒宝片治疗小儿厌食症疗效观察.山东医药,2007;47(34):82.
[56]王竞,刘利,唐进荣.葡萄糖酸锌治疗小儿厌食症50例.现代医药卫生,2005;21(10):1264.
[57]段素兰.口服锌硒宝治疗小儿厌食症62例临床观察.山西医药杂志,2008;37(2):115.
[58]李获.赛庚啶在儿科临床中的应用拓展.现代临床医学,2006;32(4):301-2.
[59]江育仁.脾健不在补贵在运.上海中医药杂志,2002;36(1):4-7.
[60]汤一新,魏睦新,熊维美等.当代小儿厌食多脾阴不足.成都中医药大学学报,2002;25(1):4-5.
[61]马生莲.二陈汤加昧治疗小儿厌食症31例.实用乡村医生杂志,2003;10(4):32.
[62]郝宏文.刘弼臣教授治疗小儿厌食症的经验.北京中医药大学学报,2003;10(1):21-22.
[63]熊文清,赖正兴,马江琼.辨证论治小儿厌食症420例.中国民族民间医药杂志,2003;63(4):211-3.
[64]姜洪林,翟兴会,金刚.小儿健身消食颗粒对脾虚证动物模型的影响.长春中医学院学报,2001;17(3):46.
[65]孙远岭,江育仁,尤汝娣,等.运脾方治疗儿童厌食症的临床及实验研究,山东中医杂志,2000;19(3):149-150.
[66]木拉提.克扎衣别克,高晓黎等.佳加消食口服液药理作用研究.西北药学杂志,2004;19(5):210-1.
[67]张月萍,杜永平,汪受传.病因模拟法建立小儿厌食症动物模型.西安医科大学学报,2000;21(4):358,359-380.
[68]隆红艳,蒋雅萍.小儿厌食症动物模型的客观标准研究.成都中医药大学学报,2005;6(28):41-2.
[69]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性利胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[70]舒章华,徐辉甫.开胃消食糖浆对幼龄大鼠β-内啡肽的调节作用.护理研究,2007;21(5):1238
[71]孙心亮.运脾开胃法治疗小儿厌食症的临床实验和文献研究,2006届硕士研究生毕业论文.
[72]吴高鑫,崔瑾,张小珊等.运脾散对厌食症动物模型大鼠血浆脑肠肽的影响.中医儿科杂志2007;3(5):11-3.
[73]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性和胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[74]Anubhuti,Arora S.Leptin and its metabolic interactions:an update.Diabetes Obes Metab.2008;10(11):973-93.
[75]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Interoceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[76].McMinn JE,Sindelar DK,Havel PJ,et al.Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.Endocrinology,2000;141(12):4442-8.
[77]陈亮.香砂六君汤治疗功能性消化不良68例.江西中医药,2003;34(3):25.
[78]林江,熊东亮,臧宁等.中西医结合治疗老年人功能性消化不良.中国中医基础医学杂志,2004;10(8):47-8.
[79]罗嗣尧.中药配合补锌治疗小儿厌食症42例.中国中西医结合脾胃杂志,1999;7(1):41-2.
[80]焦丽,李乾构.香砂六君子汤治疗慢性浅表性胃炎130例.中国中西医结合消化杂志,2008;16(1):54-55.
[81]罗远汉,李平.香砂六君子汤加味治疗慢性萎缩性胃炎38例.吉林中医药,2007;27(8):28-9.
[82]王元周,王创国.香砂六君子汤加减治疗肠激惹综合征43例.陕西中医,2006;27(1):84.
[83]王建业.香砂六君子汤加味治疗溃疡性结肠炎65例.浙江实用医学,2003;8(5):294.
[84]吴浩泉.中西医结合治疗消化性溃疡56例.井冈山医专学报,2007;14(3):32.
[85]杨坤淘.多瑞吉配合中药制剂治疗晚期癌痛的临床观察.新中医,2006;38(9):809-11.
[86]鞠少斌,邹雨荷.加味香砂六君子汤配合芬太尼透皮贴剂治疗晚期癌痛60例疗效观察.新中医,2006;38(9):55-6.
[87]贺松其,文彬,蔡红兵.香砂六君子汤加味配合多瑞吉治疗晚期癌痛42例.上海中医药杂志,2005;39(2):18-20.
[88]龙海生.香砂六君子汤对腹腔镜胆囊术后早期恢复的影响.黑龙江中医药,2006;(5):19.
[89]文译辉,粱石,梁析昭.香砂六君子汤水煎液对急性胃黏膜损伤的治疗作用.广东医学,2007;28(1):30-2.
[90]侯家玉,赵凤志,洪缨等.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究.中国中药杂志,1992;17(11):682-5.
[1]张月萍,杜永平,汪受传等.病因模拟法建立小儿厌食症动物模型.西安医科大学学报,2000;32(4):358,359-380.
[2]隆红艳,蒋雅萍.小儿厌食症动物模型的客观标准研究.成都中医药大学学报,2005;6(28):41-2.
[3]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性和胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[4]舒章华,徐辉甫.开胄消食糖浆对幼龄大鼠β-内啡肽的调节作用,护理研究;2007;21(5):1238.
[5]孙心亮,运脾开胃法治疗小儿厌食症的临床实验和文献研究,2006届硕士研究生毕业论文.
[6]吴高鑫,崔瑾,张小珊,彭玉.运脾散对厌食症动物模型大鼠血浆脑肠肽的影响,中医儿科杂志2007;3(5):11-3.
[1]Simone Munscha,Esther Biederta,Andrea H Meyera,et al.CCK,ghrelin,and PYY responses in individuals with binge eating disorder before and after a cognitive behavioral treatment(CBT).Physiology & Behavior,2009;97(1):14.
[2]D.B.Guard,T.D.Swartz,R.C.Ritter,et al.NMDANR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation.Brain Res,2009;1266:37-44.
[3]Graham J.Dockray.Cholecystokinin and gut-brain signaling Regulatory.Peptides,2007;7(6):570-4.
[4]Amelia N.Pilichiewicz,Michael Horowitz,Gerald J.Holtmann.Relationship Between Symptoms and Dietary Patterns in Patients With Functional Dyspepsia.Clinical Gastroenterology and Hepatology,2009:7(3):317-22.
[5]宋婷婷,杨德治.胆囊收缩素对消化功能的影响及其相关机制.东南大学学报(医学版),2002;21(2):190-3.
[6]Gibbs J,Young RC,Smith GP.Chokecystokinin elicits satiety in rats with open gastric fistulas.Nature,1973;245(5424):323-5.
[7]Schwartz G J,Moran TH.Integrative gastrointestinal actions of the brain-gut peptide cholecystokinin in satiety.Prog Psychobiol Physiol Psychol,1998;17:1.
[8]Parrott RF,Ebenezer IS,Forsling ML.The effects of intravenous administration of cholecystokinin on feeding behaviour and release of pituitary hormones in pigs are not mediated by serotonergic(5-HT3)receptors.Neuropharmacology,1992;31(9):863-7.
[9]A.A.Ammar,R.Nerg(?)rdh,B.B.Fredholm,et al.Intake inhibition by NPY and CCK-8:A challenge of the notion of NPY as an "Orexigen".Behavioural Brain Research,2005;161(1,3):82-7.
[10]Tennille Webb,Stephen Gulley,Fleurette Pruitt,et al.Cholecystokinin-8 increases Fos-like immunoreactivity in myenteric neurons of the duodenum and jejunum more after intraperitoneal than after intravenous injection.Neuroscience Letters,2005;389(3,9):157-62.
[11]Marvis S.Cooper,Joseph R.Reeve Jr.,Mohamed O.Abdalla.et al.Cholecystokinin-33 is more effective than cholecystokinin-8 in inhibiting food intake and in stimulating the myenteric plexus and dorsal vagal complex.Brain Research,2008;1205(18):27-35.
[12]Eva Gallmann,Denis Arsenijevic,Gareth Williams,et al.Effect of intraperitoneal CCK-8 on food intake and brain orexin-A after 48 h of fasting in the rat.Regulatory Peptides,2006;133(1-3):139-46.
[14]C.H.Vaughana,C.Haskell-Luevanob,A.Andreasenb,et al.Effects of oral preload,CCK or bombesin administration on short term food intake of melanocortin 4-receptor knockout (MC4RKO) mice.Peptides,2006;27(12):3226-33.
[15]DANIELLE GREENBERG.Fats and Satiety:The Role of the Small Intestine.Appetite,1998;31(2):229.
[16]Blevins JE,Stanley BG,Reidelberger RD.Brain regions where cholecystokinin suppresses feeding in rats.Brain Res,2000;860(1-2):1-10.
[17]Verbaeys I,Leon-Tamariz F,Buyse J,et al.PEGylated cholecystokinin prolongs satiation in rats:dose dependency and receptor involvement.Br J Pharmacol,2007;152(3):396-403.
[18]M.M.Chi,G.Fan and E.A.Fox.Increased short-term food satiation and sensitivity to cholecystokinin in neurotrophin-4 knock-in mice.Am J Physiol Regul Integr Comp Physiol,2004;287(5):R1044-53.
[19]W.Fan,K.L.Ellacott,I.G Halatchev,et al.Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system,Nat Neurosci,2004;7(4):335-6.
[20]Laurence J.Nolan PhD,Janet L.Guss MS,Rodger A.Liddle MD,et al.Elevated plasma cholecystokinin and appetitive ratings after consumption of a liquid meal in humans.Nutrition,2003;19(6):553-7.
[21]J.M.Kiely,MD,S.J.Graewin,MD,et al.Leptin Increases Small Intestinal Response to Cholecystokinin in Leptin-Deficient Obese Mice.J Surg Res,2005;124(1):146-50.
[22]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[1]J.M.Kiely,MD,S.J.Graewvin,MD,et al.Leptin Increases Small Intestinal Response to Cholecystokinin in Leptin-Deficient Obese Mice.J Surg Res,2005;124(1):146-50.
[2]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[3]CLAIRE A.MATSON,MICHAEL E WIATER,JOSEPH L.KUIJPER,et al.Synergy Between Leptin and Cholecystokinin(CCK) to Control Daily Caloric.Intake Peptides,1997;18(8):1275-8.
[4]Davidson TL,Kanoski SE,Tracy AL,et,al.The interoceptive cue properties of ghrelin generalize to cues produced by food deprivation.Peptides 2005;26(9):1602-10.
[5]Davidson TL,Kanoski SE,Walls EK,Jarrard LE.Memory inhibition and energy regulation.Physiol Behav 2005;86(5):731-46.
[6]张金国,王学忠,宋光耀等.慢性心力衰竭患者血浆瘦素水平与胰岛素抵抗、肿瘤坏死因子α的相关性研究.中华心血管病杂志,2004;32(3):271.
[7]关欣,郑红光.腹膜透析病人血浆瘦素、炎症因子与营养关系的研究.锦州医学院学报,2005;26(3):37-9.
[1]曹子鹏,王枫,向雪松等.侧脑室注射共轭亚油酸(CLA)对大鼠糖脂代谢的影响.现代生物医学进展,2007;7(4):544-7.
[2]褚文政.侧脑室注射链脲霉素引起大鼠Aβ_(1-40)和Aβ_(1-42)表达增加.第四军医大学报,2005;26(15):1356-8.
[3]于海明,王百忍,李改丽.大鼠侧脑室置管方法的改良.神经解剖学杂志,2005;21(2):207-11.
[1]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[2]王重建,杨年红.食欲调节激素与肥胖研究进展.中国公共卫生 2005;21(3):257-59.
[3]Batterham R L,Cowley M A,Small C J,et al.Gut hormone PPY(3-36) physiologically inhibits food intake.Nature,2002;418(6898):650-4.
[4]Dirk Hagemanna,Jens J.Holstb,Arnica Gethmanna,et al.Glucagon-like peptide 1(GLP-1)suppresses ghrelin levels in humans via increased insulin secretion.Regulatory Peptides,2007;143(1-3):64-8.
[5]Florian Lippl,Florian Kircher,Johannes Erdmann,et al.Effect of GIP,GLP-1,insulin and gastrin on ghrelin release in the isolated rat stomach.Regul Pept,2004;119(1-2):93-8.
[6]Chavez M,Seeley r J,Woods S C.A comparison between effects of intraventricular insulin and intraperitoneal ilthium chloride on three measures sensitive to emetic agents.Behav Neurosci,1995;109(3):547-50.
[1]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[2]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[3]Cioffi,J.A.,Shafer,A.W.,Zupancic,T.J.,et al.B219/OB receptor isoforms:possible role of leptin in hematopoiesis and reproduction.Nat Med,1996;2(5):585-9.
[4]Gainsford T,Willson T.A,Metcalf D,et al.Leptin can induce proliferation,differentiation,and functional activation of hemopoietic cells.Proc Natl Acad Sci U S A,1996;93(25):14564-8.
[5]Gema Fruhbeck.Intracellular signalling pathways activated by leptin.Biochem J,2006;393(Pt 1):7-20.
[6]Jennifer R McDuffie,Patti A Riggs,Karim A Calis,et al.Effects of Exogenous Leptin on Satiety and Satiation in Patients with Lipodystrophy and Leptin Insufficiency.J Clin Endocrinol Metab,2004;89(9):4258-63.
[7]Wren AM,Seal LJ,Cohen MA,et al.Ghrelin enhances appetite and increases food intake in humans.J Clin Endocrinol Metab,2001;86(12):5992.
[8]Cees de Graaf,Wendy AM Blom,Paul AM.Smeets Biomarkers of satiation and satiety.Am J Clin Nutr,2004;79(6):946-61.
[1]王元周,王创国.香砂六君子汤加减治疗肠激惹综合征43例.陕西中医,2006;27(1):84.
[2]王建业.香砂六君子汤加味治疗溃疡性结肠炎65例.浙江实用医学.2003;8(5):294.
[3]吴浩泉.中西医结合治疗消化性溃疡56例.井冈山医专学报.2007;14(3):32.
[4]杨坤淘.多瑞吉配合中药制剂治疗晚期癌痛的临床观察.新中医,2006;38(9):809-11.
[5]鞠少斌,邹雨荷.加味香砂六君子汤配合芬太尼透皮贴剂治疗晚期癌痛60例疗效观察.新中医,2006;38(9):55-6.
[6]贺松其,文彬,红兵.香砂六君子汤加味配合多瑞吉治疗晚期癌痛42例.上海中医药杂志,2005;39(2):18-20.
[1]葛湄菲,张春.腹痛1号治疗小儿食积腹痛的临床与实验研究.山东中医杂志,1999;18(2):62-3.
[2]张荣在,林新华,杜群等.消化片促进消化作用研究.中药药理与临床 2004;20(6):36-8.
[3]匡荣,朱社敏,倪维芳.小儿肠胃康颗粒主要药理学研究.中国现代应用药学杂志.2005;22(4):275-8.
[2]王亚红.麦芽在临床中应用说略.河南中医,2003,23(1):60.
[3]胡静,杨旭东,夏清平等.中药“神曲”对脾虚小鼠肠道菌群的调整及肠保护作用研究.中国微生态学杂志,2004;16(4):208-9.
[4]蔡子微,杨旭东,胡静等.中药神曲及其肠道茵群调整和肠保护作用的实验研究.牡丹江医学院学报,2006;27(1):1.
[5]杨继成,华新农,许惠琴等.健胃消食片的药理实验研究.南京中医药大学学报(自然科学版),2001;17(2):104-6.
[6]陈怀礼,庞春霞,李雪岩.健脾消食散对大鼠肠吸收功能的影响,河南中医药学刊,1999;14(6):20.
[7]黄保民,王寿云,李月华.开胃消食口服液对实验动物胃肠功能的影响.中医研究,1998,11(1):21-2.
[8]叶立新,邢英华,张雄等.消食贴膏对小鼠消化道功能的影响.广东药学院学报,2005,21(5):563-4.
[9]葛安霞.健脾片健脾功能的实验研究.中国中西医结合脾胃杂志,2000,8(2):85-87.
[10]Kouhei Matsuda,Kenji Kojima,Sei-Ichi Shimakura,et al.Relationship between melanin-concentrating hormone-and neuropeptide Y-containing neurons in the goldfish hypothalamus.Molecular & Integrative Physiology,2009;153(1):3-7.
[11]Goldstone AP.The hypothalamus,hormones,and hunger:alterations in human obesity and illness.Prog Brain Res,2006;153:57-73.
[12]Williams DL,Baskin DG,Schwartz MW.Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.Endocrinology,2009;150(4):1680-7.
[13]Moran TH.Cholecystokinin and satiety:current perspectives.Nutrition,2000;16(10):858-65.
[14]Verena Haas,Simone Onur,Thomas Paul,et al.Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery.Am J Clin Nutr,2005;81:889-96.
[15]Kojima M,Hosoda H,Date Y,et al.Ghrelin is a rowth-hormone-releasing acylated peptide froms to math.Nature,1999;402(6762):656.
[16]Gema Fruhbeck.Intracellular signalling pathways activated by leptin.Biochem J,2006;393(Pt 1):7-20.
[17]Laurence J,Nolan PhD,Janet L,Guss MS,et al.Elevated plasma cholecystokinin and appetitive ratings after consumption of a liquid meal in humans.Nutrition,2003;6(19):553-7.
[18]Farooqi IS,Matarese G,Lord GM,et al.Beneficial of effects of leptin on obesity,Tcell hypo responsiveness,and neuro endocrine/metabolic dysfunction of human congenital leptind eficiency.JClinlnvest,2002;110(8):1093-103.
[19]Fr(u|¨)hbeck,G.,G(?)mez-Ambrosi,J.,et al.The adipocyte:a model for integration of endocrine and metabolic signaling in energy metabolism regulation.Am J Physiol Endocrinol Metab,2001;280(6):E827-47.
[20]Fr(u|¨)hbeck,G.and G(?)mez-Ambrosi,J.Rationale for the existence of additional adipostatic hormones.FASEB J,2001;15(11):1996-2006.
[21]Mora,S.and Pessin,J.E.An adipocentric view of signaling and intracellular trafficking.Diabetes Diabetes Metab Res Rev,2002;18(5):345-56.
[22]Zhang,Y.,Proenca,R.,Maffei,M.,et al.Positional cloning of the mouse obese gene and its human homologue.Nature,1994;372(6505):425-32.
[23]Banks,W.A.The many lives of leptin.Peptides,2004;25(3):331-8.
[24]Fr'uhbeck,G.A heliocentric view of leptin.Proc.Proc Nutr Soc,2001;60(3):301-18.
[25]Fr'uhbeck,G.Peripheral actions of leptin and its involvement in disease.Nutr Rev,2002;60(10 Pt 2):S47-55.
[18]Baratta,M.Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues.Med Sci Monit,2002;8(12):RA282-92.
[26]Muoio,D.M.and Dohm,G.L.Peripheral metabolic actions of leptin.Best Pract Res Clin Endocrinol Metab,2002;16(4):653-66.
[27]Harvey,J.and Ashford,M.L.J.Leptin in the CNS:much more than a satiety signal.Neuropharmacology,2003;44(7):845-54.
[28]Bj(?)rb(?)ck,C.and Kahn,B.B.Leptin signaling in the central nervous system and the periphery.Recent Prog Horm Res,2004;59:305-31.
[29]Kinik ST,Ozbek N,Yiicel M,et al.Correlations among serum leptin levels,complete blood count parameters and peripheral CD34(+) cell count in prepubertal obese children.Ann Hematol,2005;84(9):605-8.
[30]Gualillo O,Eiras S,White DW,et al.Leptin promotes the tyrosine phosphorylation of SHC proteins and SHC association with GRB2.Mol Cell Endocrinol,2002;190(l-2):83-9.
[31]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[32]Honda K,Kamisoyama H,Saneyasu T,et al.Central administration of insulin suppresses food intake in chicks.Neurosci Lett,2007;423(2):153-7.
[33]Jennifer R McDuffie,Parti A Riggs,Karim A Calis,et al.Effects of Exogenous Leptin on Satiety and Satiation in Patients with Lipodystrophy and Leptin Insufficiency.J Clin Endocrinol Metab,2004;89(9):4258-63.
[34]Wren AM,Seal LJ,Cohen MA,et al.Ghrelin enhances appetite and increases food intake in humans.J Clin Endocrinol Metab,2004;89(6):2832.
[35]de Assis MA,Kupek E,Nahas MV,et al.Food intake and circadian rhythms in shift workers with a high workload.Appetite,2003;40(2):175-83.
[36]Matson CA,Ritter RC.Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight.Am J Physiol,1999;276(4 Pt 2):R1038-45.
[37]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Inter oceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[38]Matson CA,Wiater MF,Kuijper JL,Weigle DS.Synergy between leptin and cholecystokinin(CCK)to control daily caloric intake.Peptides,1997;18(8):1275-8.
[39]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Interoceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[40].McMinn JE,Sindelar DK,Havel PJ,et al.Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.Endocrinology,2000;141(12):4442-8.
[41]Baskin DG,Blevins JE,Schwartz MW.How the brain regulates food intake and body weight:the role of leptin.J Pediatr Endocrinol Metab,2001;14 Suppl 6:1417-29.
[42]Oral EA,Simha V,Ruiz E,et al.Leptin-replacement therapy for lipodystrophy.N Engl J Med,2002;346(25):2009.
[43]S Herguner,Ozyildirim,and G Gokcay.Behavioral approach to infantile anorexia and its outcome on maternal psychopathology.European Psychiatry,2009;24(1):S747.
[44]Chatoor I,Ganiban J,Surles J,Doussard-Roosevelt J.Physiological regulation and infantile anorexia:a pilot study.J Am Acad Child Adolesc Psychiatry.2004;43(8):1019-25.
[45]Poinso F,Viellard M,Dafonseca D,Sarles J.Infantile anorexia:from birth to childhood.Arch Pediatr.2006;13(5):464-72.
[46]Irene Chatoor MD,Jaclyn Surles,BA,Jody Ganiban.Failure to thrive and cognitive development in toddlers with infantile anorexia.Pediatrics,2004;112(5):e440-7.
[47]张丽萍,耿丽,范瑞君.小儿厌食症相关因素调查,武警医学,2008;19(9):784-6.
[48]曾国章.厌食症发病相关因素研究.中国妇幼保健,2008;23(27):3840-1
[49]王研,赵海涛,张劲松等.厌食儿童和正常儿童食物刺激下丘脑功能区fMRI的研究 神经解剖学杂志,2008;24(1):58-62.
[50]陈志凤.厌食症儿童血Ghrelin、Leptin与NPY的水平变化及其临床意义.中国优秀博硕士学位论文全文数据库(硕士),2006,(08).
[51]候菊鲜,岳淑芬,王京红.厌食痖患儿血清中铁锌铜锰硒含量的研究.广东微量元素科学,1999;(2):35-37.
[52]陈美华,罗文莉,张静等.普瑞博斯治疗小儿厌食症疗效观测.白求恩军医学院学报,2004;2(4).
[53]宋春兰,杜开先.口服金双岐治疗小儿厌食症42例.河南预防医学杂志,2007;18(3):224-5.
[54]林顺利,林东浩.双歧杆菌四联活菌片与白苓健脾颗粒联合治疗小儿厌食症.河北医学,2008;14(12).
[55]孟付忠.锌硒宝片治疗小儿厌食症疗效观察.山东医药,2007;47(34):82.
[56]王竞,刘利,唐进荣.葡萄糖酸锌治疗小儿厌食症50例.现代医药卫生,2005;21(10):1264.
[57]段素兰.口服锌硒宝治疗小儿厌食症62例临床观察.山西医药杂志,2008;37(2):115.
[58]李获.赛庚啶在儿科临床中的应用拓展.现代临床医学,2006;32(4):301-2.
[59]江育仁.脾健不在补贵在运.上海中医药杂志,2002;36(1):4-7.
[60]汤一新,魏睦新,熊维美等.当代小儿厌食多脾阴不足.成都中医药大学学报,2002;25(1):4-5.
[61]马生莲.二陈汤加昧治疗小儿厌食症31例.实用乡村医生杂志,2003;10(4):32.
[62]郝宏文.刘弼臣教授治疗小儿厌食症的经验.北京中医药大学学报,2003;10(1):21-22.
[63]熊文清,赖正兴,马江琼.辨证论治小儿厌食症420例.中国民族民间医药杂志,2003;63(4):211-3.
[64]姜洪林,翟兴会,金刚.小儿健身消食颗粒对脾虚证动物模型的影响.长春中医学院学报,2001;17(3):46.
[65]孙远岭,江育仁,尤汝娣,等.运脾方治疗儿童厌食症的临床及实验研究,山东中医杂志,2000;19(3):149-150.
[66]木拉提.克扎衣别克,高晓黎等.佳加消食口服液药理作用研究.西北药学杂志,2004;19(5):210-1.
[67]张月萍,杜永平,汪受传.病因模拟法建立小儿厌食症动物模型.西安医科大学学报,2000;21(4):358,359-380.
[68]隆红艳,蒋雅萍.小儿厌食症动物模型的客观标准研究.成都中医药大学学报,2005;6(28):41-2.
[69]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性利胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[70]舒章华,徐辉甫.开胃消食糖浆对幼龄大鼠β-内啡肽的调节作用.护理研究,2007;21(5):1238
[71]孙心亮.运脾开胃法治疗小儿厌食症的临床实验和文献研究,2006届硕士研究生毕业论文.
[72]吴高鑫,崔瑾,张小珊等.运脾散对厌食症动物模型大鼠血浆脑肠肽的影响.中医儿科杂志2007;3(5):11-3.
[73]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性和胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[74]Anubhuti,Arora S.Leptin and its metabolic interactions:an update.Diabetes Obes Metab.2008;10(11):973-93.
[75]Scott E Kanoski,Elwood K Walls and T.L.Davidson.Interoceptive "satiety" signals produced by leptin and CCK.Peptides.2007,28(5):988-1002.
[76].McMinn JE,Sindelar DK,Havel PJ,et al.Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin.Endocrinology,2000;141(12):4442-8.
[77]陈亮.香砂六君汤治疗功能性消化不良68例.江西中医药,2003;34(3):25.
[78]林江,熊东亮,臧宁等.中西医结合治疗老年人功能性消化不良.中国中医基础医学杂志,2004;10(8):47-8.
[79]罗嗣尧.中药配合补锌治疗小儿厌食症42例.中国中西医结合脾胃杂志,1999;7(1):41-2.
[80]焦丽,李乾构.香砂六君子汤治疗慢性浅表性胃炎130例.中国中西医结合消化杂志,2008;16(1):54-55.
[81]罗远汉,李平.香砂六君子汤加味治疗慢性萎缩性胃炎38例.吉林中医药,2007;27(8):28-9.
[82]王元周,王创国.香砂六君子汤加减治疗肠激惹综合征43例.陕西中医,2006;27(1):84.
[83]王建业.香砂六君子汤加味治疗溃疡性结肠炎65例.浙江实用医学,2003;8(5):294.
[84]吴浩泉.中西医结合治疗消化性溃疡56例.井冈山医专学报,2007;14(3):32.
[85]杨坤淘.多瑞吉配合中药制剂治疗晚期癌痛的临床观察.新中医,2006;38(9):809-11.
[86]鞠少斌,邹雨荷.加味香砂六君子汤配合芬太尼透皮贴剂治疗晚期癌痛60例疗效观察.新中医,2006;38(9):55-6.
[87]贺松其,文彬,蔡红兵.香砂六君子汤加味配合多瑞吉治疗晚期癌痛42例.上海中医药杂志,2005;39(2):18-20.
[88]龙海生.香砂六君子汤对腹腔镜胆囊术后早期恢复的影响.黑龙江中医药,2006;(5):19.
[89]文译辉,粱石,梁析昭.香砂六君子汤水煎液对急性胃黏膜损伤的治疗作用.广东医学,2007;28(1):30-2.
[90]侯家玉,赵凤志,洪缨等.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究.中国中药杂志,1992;17(11):682-5.
[1]张月萍,杜永平,汪受传等.病因模拟法建立小儿厌食症动物模型.西安医科大学学报,2000;32(4):358,359-380.
[2]隆红艳,蒋雅萍.小儿厌食症动物模型的客观标准研究.成都中医药大学学报,2005;6(28):41-2.
[3]吴丽萍,王艳丽.小儿增食灵合剂对小儿厌食症动物模型胃蛋白酶活性和胃酸分泌量的影响.中医儿科杂志,2007;3(3):26-8.
[4]舒章华,徐辉甫.开胄消食糖浆对幼龄大鼠β-内啡肽的调节作用,护理研究;2007;21(5):1238.
[5]孙心亮,运脾开胃法治疗小儿厌食症的临床实验和文献研究,2006届硕士研究生毕业论文.
[6]吴高鑫,崔瑾,张小珊,彭玉.运脾散对厌食症动物模型大鼠血浆脑肠肽的影响,中医儿科杂志2007;3(5):11-3.
[1]Simone Munscha,Esther Biederta,Andrea H Meyera,et al.CCK,ghrelin,and PYY responses in individuals with binge eating disorder before and after a cognitive behavioral treatment(CBT).Physiology & Behavior,2009;97(1):14.
[2]D.B.Guard,T.D.Swartz,R.C.Ritter,et al.NMDANR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation.Brain Res,2009;1266:37-44.
[3]Graham J.Dockray.Cholecystokinin and gut-brain signaling Regulatory.Peptides,2007;7(6):570-4.
[4]Amelia N.Pilichiewicz,Michael Horowitz,Gerald J.Holtmann.Relationship Between Symptoms and Dietary Patterns in Patients With Functional Dyspepsia.Clinical Gastroenterology and Hepatology,2009:7(3):317-22.
[5]宋婷婷,杨德治.胆囊收缩素对消化功能的影响及其相关机制.东南大学学报(医学版),2002;21(2):190-3.
[6]Gibbs J,Young RC,Smith GP.Chokecystokinin elicits satiety in rats with open gastric fistulas.Nature,1973;245(5424):323-5.
[7]Schwartz G J,Moran TH.Integrative gastrointestinal actions of the brain-gut peptide cholecystokinin in satiety.Prog Psychobiol Physiol Psychol,1998;17:1.
[8]Parrott RF,Ebenezer IS,Forsling ML.The effects of intravenous administration of cholecystokinin on feeding behaviour and release of pituitary hormones in pigs are not mediated by serotonergic(5-HT3)receptors.Neuropharmacology,1992;31(9):863-7.
[9]A.A.Ammar,R.Nerg(?)rdh,B.B.Fredholm,et al.Intake inhibition by NPY and CCK-8:A challenge of the notion of NPY as an "Orexigen".Behavioural Brain Research,2005;161(1,3):82-7.
[10]Tennille Webb,Stephen Gulley,Fleurette Pruitt,et al.Cholecystokinin-8 increases Fos-like immunoreactivity in myenteric neurons of the duodenum and jejunum more after intraperitoneal than after intravenous injection.Neuroscience Letters,2005;389(3,9):157-62.
[11]Marvis S.Cooper,Joseph R.Reeve Jr.,Mohamed O.Abdalla.et al.Cholecystokinin-33 is more effective than cholecystokinin-8 in inhibiting food intake and in stimulating the myenteric plexus and dorsal vagal complex.Brain Research,2008;1205(18):27-35.
[12]Eva Gallmann,Denis Arsenijevic,Gareth Williams,et al.Effect of intraperitoneal CCK-8 on food intake and brain orexin-A after 48 h of fasting in the rat.Regulatory Peptides,2006;133(1-3):139-46.
[14]C.H.Vaughana,C.Haskell-Luevanob,A.Andreasenb,et al.Effects of oral preload,CCK or bombesin administration on short term food intake of melanocortin 4-receptor knockout (MC4RKO) mice.Peptides,2006;27(12):3226-33.
[15]DANIELLE GREENBERG.Fats and Satiety:The Role of the Small Intestine.Appetite,1998;31(2):229.
[16]Blevins JE,Stanley BG,Reidelberger RD.Brain regions where cholecystokinin suppresses feeding in rats.Brain Res,2000;860(1-2):1-10.
[17]Verbaeys I,Leon-Tamariz F,Buyse J,et al.PEGylated cholecystokinin prolongs satiation in rats:dose dependency and receptor involvement.Br J Pharmacol,2007;152(3):396-403.
[18]M.M.Chi,G.Fan and E.A.Fox.Increased short-term food satiation and sensitivity to cholecystokinin in neurotrophin-4 knock-in mice.Am J Physiol Regul Integr Comp Physiol,2004;287(5):R1044-53.
[19]W.Fan,K.L.Ellacott,I.G Halatchev,et al.Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system,Nat Neurosci,2004;7(4):335-6.
[20]Laurence J.Nolan PhD,Janet L.Guss MS,Rodger A.Liddle MD,et al.Elevated plasma cholecystokinin and appetitive ratings after consumption of a liquid meal in humans.Nutrition,2003;19(6):553-7.
[21]J.M.Kiely,MD,S.J.Graewin,MD,et al.Leptin Increases Small Intestinal Response to Cholecystokinin in Leptin-Deficient Obese Mice.J Surg Res,2005;124(1):146-50.
[22]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[1]J.M.Kiely,MD,S.J.Graewvin,MD,et al.Leptin Increases Small Intestinal Response to Cholecystokinin in Leptin-Deficient Obese Mice.J Surg Res,2005;124(1):146-50.
[2]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[3]CLAIRE A.MATSON,MICHAEL E WIATER,JOSEPH L.KUIJPER,et al.Synergy Between Leptin and Cholecystokinin(CCK) to Control Daily Caloric.Intake Peptides,1997;18(8):1275-8.
[4]Davidson TL,Kanoski SE,Tracy AL,et,al.The interoceptive cue properties of ghrelin generalize to cues produced by food deprivation.Peptides 2005;26(9):1602-10.
[5]Davidson TL,Kanoski SE,Walls EK,Jarrard LE.Memory inhibition and energy regulation.Physiol Behav 2005;86(5):731-46.
[6]张金国,王学忠,宋光耀等.慢性心力衰竭患者血浆瘦素水平与胰岛素抵抗、肿瘤坏死因子α的相关性研究.中华心血管病杂志,2004;32(3):271.
[7]关欣,郑红光.腹膜透析病人血浆瘦素、炎症因子与营养关系的研究.锦州医学院学报,2005;26(3):37-9.
[1]曹子鹏,王枫,向雪松等.侧脑室注射共轭亚油酸(CLA)对大鼠糖脂代谢的影响.现代生物医学进展,2007;7(4):544-7.
[2]褚文政.侧脑室注射链脲霉素引起大鼠Aβ_(1-40)和Aβ_(1-42)表达增加.第四军医大学报,2005;26(15):1356-8.
[3]于海明,王百忍,李改丽.大鼠侧脑室置管方法的改良.神经解剖学杂志,2005;21(2):207-11.
[1]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[2]王重建,杨年红.食欲调节激素与肥胖研究进展.中国公共卫生 2005;21(3):257-59.
[3]Batterham R L,Cowley M A,Small C J,et al.Gut hormone PPY(3-36) physiologically inhibits food intake.Nature,2002;418(6898):650-4.
[4]Dirk Hagemanna,Jens J.Holstb,Arnica Gethmanna,et al.Glucagon-like peptide 1(GLP-1)suppresses ghrelin levels in humans via increased insulin secretion.Regulatory Peptides,2007;143(1-3):64-8.
[5]Florian Lippl,Florian Kircher,Johannes Erdmann,et al.Effect of GIP,GLP-1,insulin and gastrin on ghrelin release in the isolated rat stomach.Regul Pept,2004;119(1-2):93-8.
[6]Chavez M,Seeley r J,Woods S C.A comparison between effects of intraventricular insulin and intraperitoneal ilthium chloride on three measures sensitive to emetic agents.Behav Neurosci,1995;109(3):547-50.
[1]Qu S,Zou D J.Expression of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet.Chin J Endocrinol Metab,2003,19(3):210.
[2]Scott E.Kanoski,Elwood K.Walls,T.L.Davidson.Interoceptive"satiety"signals produced by leptin and CCK.Peptides,2007;28(5):988-1002.
[3]Cioffi,J.A.,Shafer,A.W.,Zupancic,T.J.,et al.B219/OB receptor isoforms:possible role of leptin in hematopoiesis and reproduction.Nat Med,1996;2(5):585-9.
[4]Gainsford T,Willson T.A,Metcalf D,et al.Leptin can induce proliferation,differentiation,and functional activation of hemopoietic cells.Proc Natl Acad Sci U S A,1996;93(25):14564-8.
[5]Gema Fruhbeck.Intracellular signalling pathways activated by leptin.Biochem J,2006;393(Pt 1):7-20.
[6]Jennifer R McDuffie,Patti A Riggs,Karim A Calis,et al.Effects of Exogenous Leptin on Satiety and Satiation in Patients with Lipodystrophy and Leptin Insufficiency.J Clin Endocrinol Metab,2004;89(9):4258-63.
[7]Wren AM,Seal LJ,Cohen MA,et al.Ghrelin enhances appetite and increases food intake in humans.J Clin Endocrinol Metab,2001;86(12):5992.
[8]Cees de Graaf,Wendy AM Blom,Paul AM.Smeets Biomarkers of satiation and satiety.Am J Clin Nutr,2004;79(6):946-61.
[1]王元周,王创国.香砂六君子汤加减治疗肠激惹综合征43例.陕西中医,2006;27(1):84.
[2]王建业.香砂六君子汤加味治疗溃疡性结肠炎65例.浙江实用医学.2003;8(5):294.
[3]吴浩泉.中西医结合治疗消化性溃疡56例.井冈山医专学报.2007;14(3):32.
[4]杨坤淘.多瑞吉配合中药制剂治疗晚期癌痛的临床观察.新中医,2006;38(9):809-11.
[5]鞠少斌,邹雨荷.加味香砂六君子汤配合芬太尼透皮贴剂治疗晚期癌痛60例疗效观察.新中医,2006;38(9):55-6.
[6]贺松其,文彬,红兵.香砂六君子汤加味配合多瑞吉治疗晚期癌痛42例.上海中医药杂志,2005;39(2):18-20.
[1]葛湄菲,张春.腹痛1号治疗小儿食积腹痛的临床与实验研究.山东中医杂志,1999;18(2):62-3.
[2]张荣在,林新华,杜群等.消化片促进消化作用研究.中药药理与临床 2004;20(6):36-8.
[3]匡荣,朱社敏,倪维芳.小儿肠胃康颗粒主要药理学研究.中国现代应用药学杂志.2005;22(4):275-8.